AT-61

AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection[1].

Product Specifications

CAS Number

[300669-68-5]

UNSPSC

12352005

Target

HBV

Related Pathways

Anti-infection

Field of Research

Infection

Smiles

O=C(C1=CC=CC=C1)N/C(C(N2CCCCC2)=O)=C(C3=CC=CC=C3)/Cl

Molecular Formula

C21H21ClN2O2

Molecular Weight

368.86

References & Citations

[1]Billioud G, et al. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication. Antiviral Res. 2011 Nov;92 (2) :271-6. |[2]Ren Q, et al. 3- ((R) -4- (((R) -6- (2-Bromo-4-fluorophenyl) -5- (ethoxycarbonyl) -2- (thiazol-2-yl) -3,6-dihydropyrimidin-4-yl) methyl) morpholin-2-yl) propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4. J Med Chem. 2018 Feb 8;61 (3) :1355-1374.